Somatus
Somatus is a healthcare company providing value-based kidney care through integrated services and technology to delay or prevent disease.
Secondary Market Price
How Somatus Measures Up
To help you manage your Somatus equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
TBD
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Somatus's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Somatus Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Somatus's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Somatus is a kidney care company that provides value-based care for patients with or at risk of developing kidney disease. The company partners with health plans, health systems, and physician groups to deliver integrated clinical services and technology aimed at preventing or delaying disease progression. Its services include population health and renal care management, support for social determinants of health like nutrition and transportation, and a technology platform that offers personalized health records and secure messaging between patients and care teams. Founded in 2016 and headquartered in McLean, Virginia, the privately held company has grown to include a network of over 100 nephrology groups and more than 1,500 nephrologists.
Looking ahead, Somatus has stated it has developments planned for 2026 and intends to continue expanding its provider network and deploying new payment integrity solutions for health plans and Accountable Care Organizations (ACOs). The company's recent performance metrics, shared in late 2025, reported a 13% relative reduction in mortality, a 17% relative reduction in medical costs, and a 31% relative improvement in hospitalization rates for patients participating in its program. The company also continues to actively recruit for clinical and care management roles to support its operations.
- Wellington Management
- RA Capital Management
- GIC
- Fidelity Management & Research Company
- Anthem
- Blue Venture Fund
- Deerfield Management Company
- Flare Capital Partners
- Inova Health System
- Longitude Capital
- Optum Ventures
- Co-Founder, Ikenna Okezie
- Co-Founder, Anthony Welters
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Somatus worth joining?
Deciding whether to join a startup like Somatus depends on your personal career and financial goals, as well as your assessment of the company's potential. Tools like Prospect can help you evaluate the equity component of your offer by modeling its potential future value.
What should I do with my Somatus stock?
Managing your Somatus stock involves creating a strategy for exercising options and selling shares that aligns with your financial goals and minimizes your tax burden. Platforms like Prospect build customized, multi-year plans to help you make these decisions and maximize your equity's value.
Can you sell Somatus stock?
Since Somatus is a private company, its stock is not publicly traded and can typically only be sold during specific events like tender offers or secondary sales. Prospect offers tools and guidance to help you navigate these limited liquidity opportunities and decide when and how much to sell.
How can I find the value of my Somatus stock?
The official value of your Somatus stock is its current 409A valuation, but this doesn't reflect its potential future worth. To better understand what your equity could be worth, Prospect uses predictive models to forecast a range of potential outcomes for your shares.
What is Somatus's equity worth?
The overall valuation of Somatus is established during its private funding rounds and can fluctuate between them. For an individual employee, understanding the net value of your specific equity grant requires modeling taxes and other costs, which is a service provided by platforms like Prospect.
What is Somatus's stock ticker symbol?
Somatus does not have a stock ticker symbol because it is a private company and its shares are not available on public stock exchanges. A ticker symbol will only be assigned if the company decides to go public through an IPO.
Can I buy or sell Somatus stock?
As an employee, you can "buy" stock by exercising your options, but you generally cannot purchase additional shares on an open market. Selling is restricted to specific company-approved windows, and Prospect provides strategies for both exercising options and selling shares when opportunities arise.
What is the criteria to buy or invest in Somatus stock?
Investing in Somatus is generally restricted to accredited investors participating in official funding rounds. For employees, the opportunity to invest comes from exercising your stock options, a decision that platforms like Prospect can help you time correctly to optimize financial outcomes.
